ARTICLES ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
|
|
- Mervin West
- 6 years ago
- Views:
Transcription
1 ARTICLES ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease A. Di Fonzo, MD H.F. Chien, MD M. Socal, MD S. Giraudo, BS C. Tassorelli, MD G. Iliceto, MD G. Fabbrini, MD R. Marconi, MD E. Fincati, MD G. Abbruzzese, MD P. Marini, MD F. Squitieri, MD M.W. Horstink, MD, PhD P. Montagna, MD A. Dalla Libera, MD F. Stocchi, MD S. Goldwurm, MD, PhD J.J. Ferreira, MD G. Meco, MD E. Martignoni, MD L. Lopiano, MD L.B. Jardim, MD, PhD B.A. Oostra, PhD E.R. Barbosa, MD The Italian Parkinson Genetics Network* V. Bonifati, MD, PhD Address correspondence and reprint requests to Dr. V. Bonifati, Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands See also page 1553 Supplemental data at ABSTRACT Objective: To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset 21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD). Methods: We studied 46 patients, mostly from Italy or Brazil, including 11 with juvenile parkinsonism and 35 with YOPD. Thirty-three cases were sporadic and 13 had positive family history compatible with autosomal recessive inheritance. Forty-two had only parkinsonian signs, while four (all juvenile-onset) had multisystemic involvement. The whole ATP13A2 coding region (29 exons) and exon-intron boundaries were sequenced from genomic DNA. Results: A novel homozygous missense mutation (Gly504Arg) was identified in one sporadic case from Brazil with juvenile parkinsonism. This patient had symptoms onset at age 12, levodopa-responsive severe akinetic-rigid parkinsonism, levodopa-induced motor fluctuations and dyskinesias, severe visual hallucinations, and supranuclear vertical gaze paresis, but no pyramidal deficit nor dementia. Brain CT scan showed moderate diffuse atrophy. Furthermore, two Italian cases with YOPD without atypical features carried a novel missense mutation (Thr12Met, Gly533Arg) in single heterozygous state. Conclusions: We confirm that ATP13A2 homozygous mutations are associated with human parkinsonism, and expand the associated genotypic and clinical spectrum, by describing a homozygous missense mutation in this gene in a patient with a phenotype milder than that initially associated with ATP13A2 mutations (Kufor-Rakeb syndrome). Our data also suggest that ATP13A2 single heterozygous mutations might be etiologically relevant for patients with YOPD and further studies of this gene in Parkinson disease are warranted. NEUROLOGY 2007;68: The term juvenile parkinsonism is conventionally used to indicate patients with onset of a parkinsonian syndrome before the age of 21 years. If onset is between age of 21 and 40 years, the term young onset Parkinson disease (YOPD) is preferred. 1,2 A distinct juvenile multisystemic neurodegenerative disease was described in 1994 in a consanguineous family from Jordan (Kufor-Rakeb disease, KRD). 3 Five siblings had akineticrigid parkinsonism of subacute, juvenile onset (around age 13) which responded to levodopa, pyramidal tract dysfunction, supranuclear gaze paresis, and dementia. Despite the presence of a good response to levodopa, this syndrome is therefore distinct from PD, and close (though not identical to) the rare Davison pallido-pyramidal degeneration. 4 A more recent clinical follow-up study of the KRD family described the presence of additional features such as visual hallucinations, facial-faucial-finger mini-myoclonus (FFF), and oculogyric dystonic *Members of the Italian Parkinson Genetics Network are listed in the appendix. From the Department of Clinical Genetics (A. Di Fonzo, B.A.O., V.B.), Erasmus MC, Rotterdam, The Netherlands; Department of Neurology (H.F.C., E.R.B.), University of São Paulo, Brazil; Hospital de Clínicas de Porto Alegre (M.S., L.B.J.), Brazil; Department of Neuroscience (S. Giraudo, L.L.), University of Turin, Italy; Institute IRCCS Mondino (C.T.), Pavia, Italy; Department of Neurology (G.I.), University of Bari, Italy; Department of Neurological Sciences (G.F., G.M.), La Sapienza University, Rome; Neurology Division (R.M.), Misericordia Hospital, Grosseto, Italy; Department of Neurology (E.F.), University of Verona, Italy; Department of Neurosciences (G.A.), Ophthalmology & Genetics, University of Genova, Italy; Department of Neurology (P. Marini), University of Florence, Italy; Neurogenetics Unit (F. Squitieri), IRCCS Neuromed, Pozzilli, Italy; Department of Neurology (M.W.H.), Radboud University Nijmegen Medical Center, Netherlands; Department of Neurology (P. Montagna), University of Bologna, Italy; Neurology Division (A. Dalla Libera), Boldrini Hospital, Thiene, Italy; IRCCS San Raffaele Pisana (F. Stocchi), Rome, Italy; Parkinson Institute (S. Goldwurm), Istituti Clinici di Perfezionamento, Milan; Neurological Clinical Research Unit (J.J.F.), Institute of Molecular Medicine, Lisbon, Portugal; A. Avogadro University (E.M.), Novara, and Institute IRCCS S. Maugeri, Scientific Institute of Veruno, Italy; and Department of Neurological Sciences, University of Milan, and Foundation Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena (A. Di Fonzo), Milan, Italy. The Italian control DNA samples were from the Human Genetic Bank of Patients Affected by PD and Parkinsonisms, Parkinson Institute Istituti Clinici di Perfezionamento, Milan, supported by the Italian Telethon Foundation (grant GTF04007). Supported by a research grant from the Internationaal Parkinson Fonds (The Netherlands) to V.B. Disclosure: The authors report no conflicts of interest. Copyright 2007 by AAN Enterprises, Inc. 1557
2 (A) Electropherograms of fragments of the ATP13A2 genomic sequence. The position of the mutations identified in this study is indicated. The corresponding sequence from unrelated healthy controls is provided as a reference. (B) Conservation of the ATP13A2 protein residues targeted by the mutations identified in patients. The closest homologues of the ATP13A2 protein were aligned using the program ClustalW. GenBank accession numbers are as follows: NP_ (ATPase type 13A2, Homo sapiens); XP_ (similar to ATPase type 13A2 isoform 2, Macaca mulatta); NP_ (ATPase type 13A2, Mus musculus); XP_ (similar to ATPase type 13A2, Rattus norvegicus); AAH (MGC84593 protein, Xenopus laevis); AAN (Q8IMA, Drosophila melanogaster). (C) Schematic representation of the ATP13A2 protein, its predicted functional domains, and position of the mutations identified in this study. The homozygous mutation (Gly504Arg) is underlined. Figure 1 Molecular findings spasms. 5 The pathology of KRD remains unexplored, but neuroimaging showed progressive, diffuse brain atrophy. 3,5 A genetic locus was mapped to the chromosome 1p36 region in the original KRD family and termed PARK9. 6 Linkage was recently confirmed in a second pedigree originating from Chile with a similar phenotype, and pathogenic, homozygous, and compound heterozygous loss-of-function mutations in the ATP13A2 gene were identified in these two kindreds. 7 Whether ATP13A2 mutations are also associated with pure juvenile parkinsonism or YOPD remains currently unknown. We sequenced the complete ATP13A2 coding region in 46 patients with parkinsonism of juvenile or young onset, and we identified three novel ATP13A2 missense mutations, including one homozygous mutation. METHODS Forty-six index patients from two cohorts of consecutively collected familial and sporadic cases were included in this study. Thirteen patients were from families compatible with autosomal recessive inheritance of parkinsonism ( 2 affected siblings and unaffected parents) and onset before age 40 years (average: 29, range 10 to 40 years) (AR cohort). Four of these cases had onset before 21 years (juvenile parkinsonism) and the remaining nine had YOPD. Among these families, eight were from Italy, four from Brazil, and one from The Netherlands. The remaining 33 patients had sporadic parkinsonism (no first-degree relatives affected by PD) and disease onset before age 33 years (average 26, range 10 to 33 years). Seven of these cases had juvenile parkinsonism and 26 had YOPD. Among the sporadic cases, 22 were from Italy, 10 from Brazil, and 1 from Japan. Parental consanguinity was reported in three of the AR families and in three sporadic cases. Mutations in the parkin, 8 PINK1, 9 and DJ-1 10 gene were previously excluded in all the familial and most of the sporadic cases included in this study. Forty-two cases (35 with YOPD and 7 juvenile parkinsonism) had a pure parkinsonian syndrome (bradykinesia and at least one of the following: resting tremor, rigidity, and postural instability); progressive course; positive response to dopaminergic therapy; and no atypical features or known causes of parkinsonism. The remaining four index cases were two familial (one Italian and one Dutch) and two sporadic Brazilian patients with juvenile parkinsonism and additional clinical features such as pyramidal signs, supranuclear gaze paresis, or cognitive deterioration, resembling thereby the pallidopyramidal degeneration or KRD. Neurologic examination included the Unified Parkinson s Disease Rating Scale (UPDRS, motor part), 11 Hoehn-Yahr scale, and Mini-Mental State Examination. The novel sequence variants detected in patients were tested in ethnically matched healthy controls (140 Italian and 109 Portuguese subjects, mainly spouses of patients) free from PD or dementia, aged 50 years and recruited at the Milan and Lisbon centers. Moreover, 78 additional unrelated Brazilian patients with early-onset PD, recruited at São Paulo and Porto Alegre centers, were screened for the mutation found in one Brazilian index. The relevant ethical authorities approved the study and written informed consent was obtained from all subjects. Genomic DNA was isolated from peripheral blood using standard protocols. The 29 exons and intron-exon boundaries of the ATP13A2 gene were amplified using PCR. For sequencing of some exons, additional internal primers were also used. All primer sequences, PCR conditions, and sequencing methods are reported in table E-1 on the Neurology Web site at www. neurology.org. The mutations were numbered from the A of the ATG-translation initiation codon, and the consequences of mutations at the protein level were predicted according to the ATP13A2 mrna sequence (GenBank accession number NM_ ) and protein sequence (accession number NP_ ). RESULTS In one sporadic patient from Brazil (BR- 3042), genomic sequencing of ATP13A2 revealed a novel homozygous g1510c mutation in exon 15, predicted to cause the missense Gly504Arg change in the encoded protein (figure 1A). The presence of the mutation in heterozygous state was confirmed in both his unaffected parents. Furthermore, novel single heterozygous missense mutations were found in two Italian cases: c35t in exon 2, predicted protein effect: Thr12Met in one sporadic case (VE-29); and g1597a in exon 16, pre Neurology 68 May 8, 2007
3 Table Clinical features in patients with ATP13A2 mutations Patient BR-3042 Patient VE-29 Patient PK Mutation Gly504Arg Thr12Met Gly533Arg Zygosity Homozygous Heterozygous Heterozygous Gender Male Male Male Onset age, y Duration, y UPDRS NA Bradykinesia Rigidity Tremor in extremities Postural instability NA Asymmetric onset L-Dopa response Motor fluctuations NA Dyskinesias NA Hallucinations Psychotic episodes Supranuclear gaze paresis Babinski sign Dementia Brain imaging Diffuse atrophy (CT) Normal (MRI) Normal (MRI) Other features Lip/chin tremor Sleep benefit Obsessive-compulsive disturbance UPDRS Unified Parkinson s Disease Rating Scale; NA not available. dicted protein effect: Gly533Arg, in one familial patient (PK-69-01) (figure 1A). In these cases, direct sequencing of genomic DNA did not detect additional variants. Due to the lack of mrna samples, cdna studies could not be performed. One brother of the PK case was also affected by earlyonset PD, but DNA samples for co-segregation studies were not available. A novel exonic, silent variant (c1005t, predicted protein effect: Ala335Ala) was detected in heterozygous state in one patient (TOR-97). Many known single nucleotide polymorphisms (SNPs) were also detected in several cases in heterozygous or homozygous state, but none of these leads to amino acid change in the protein: c1815t (Pro605Pro), c2637t (Gly879Gly), g2790a (Ser930Ser), g2970a (Val990Val), c3192t (Ala1064Ala), and g3516a (Pro1172Pro). The Gly504Arg mutation was not observed in 498 chromosomes from healthy individuals, including 218 from the Portuguese and 280 from the Italian population. Moreover, this mutation was absent from 156 chromosomes from Brazilian patients with early-onset PD. The remaining two missense mutations were not found in 240 chromosomes from healthy Italian individuals. Furthermore, the missense mutations identified in this study all replace highly conserved residues in the ATP13A2 protein (figure 1B). The most important clinical features in the patients carrying ATP13A2 mutations are reported in the table. CASE REPORT The patient with homozygous missense ATP13A2 mutation (BR-3042) is the youngest of four siblings born from a nonconsanguineous Brazilian couple of white ethnicity. They were unable to trace back the exact geographic origin of their ancestors. No other cases of parkinsonism are reported in the family. He had normal developmental milestones, finished high school smoothly, and, even after many years of disease and severe motor disability, he applied for college and passed the examinations with excellent grades. At the age of 12 the subject s family, friends, and teachers noticed that he was very slow and his movements were awkward and clumsy. One year after the onset of symptoms, a diagnosis of juvenile PD was made. In 2002, 6 years later, he was seen by some of us (H.F.C., E.R.B.) at the Department of Neurology, University of São Paulo. He showed an initial very good response to levodopa and bromocriptine. However, soon thereafter he developed choreic dyskinesias and visual hallucinations, which Neurology 68 May 8,
4 Images obtained in the patient with homozygous ATP13A2 mutation, after 10 years of disease course. A diffuse moderate atrophy is evident in both the cerebral and cerebellar structures. Figure 2 Brain CT images worsened over months and were later accompanied by episodes of aggressive behavior, for which he required hospitalization and treatment with haloperidol. Bromocriptine was then stopped and a combination of only levodopa/benserazide and atypical antipsychotics (quetiapine) allowed satisfactory control of motor and psychic symptoms. Over the last year the parkinsonism worsened with re-emergence of hallucinations and severe fluctuations and dyskinesias, requiring repeated changes in the drug schedule, including the combination of entacapone and levodopa. The therapeutic window is now narrowed to the extent that he has alternating periods of severe akinetic-rigid states (when off ) and severe dyskinesias and psychiatric disturbances (when on ). He never had tremor in his extremities. Currently, his mental status remains very good: he scored 29 on MMSE and was very well informed on political facts. However, detailed neuropsychological testing could not be performed. To prevent side effects, he is currently taking only small amounts of drugs (levodopa [plus benserazide] 350 mg/day; quetiapine 50 mg/day), and his neurologic examination is dominated by severe akinetic-rigid parkinsonism (H-Y stage V; UPDRS motor score 65/108). A limitation in upward gaze is also present. Deep tendon reflexes are brisk but Babinski sign is absent. He has no sphincter problems. There is no tremor in the extremities. A very mild tremor is noticed in the lower lip and chin when he is talking, but other movement disorders such as the FFF described in patients with KRD 5 are not observed. A brain CT scan performed in 2006, after 10 years of disease course, showed diffuse moderate atrophy in both the cerebral and cerebellar structures (figure 2). DISCUSSION We provide independent confirmation that homozygous ATP13A2 gene mutations are associated with human neurodegeneration. We also expand the genotypic spectrum describing missense mutations in this gene. In contrast, the mutations reported in the two original families with KRD were more dramatic, leading to premature truncation or in-frame absence of a long fragment of the encoded protein. 7 The Gly504Arg is not an obvious loss-offunction mutation, and the absence of other PD cases in the family precluded further co-segregation study. Due to this, it is difficult to conclusively prove pathogenicity. However, several arguments strongly support the view that this mutation is disease causing in the BR-3042 patient. We did not observe the Gly504Arg mutation, even in heterozygous state, in any of the controls or any other Brazilian patients with PD (total: 654 chromosomes tested), while it is present in homozygous state in the BR patient and in heterozygous state in both his unaffected parents. The Gly504 residue is highly conserved in the known mammalian homologues of the ATP13A2 protein (figure 1B), and is located in the larger cytosolic loop close to the predicted catalytic phosphorylation site (figure 1C). The mutation introduces a non-conservative change, by replacing glycine, a small neutral amino acid, with the large and positively charged arginine. This modification might therefore affect the biochemical properties of this region. The interpretation of the role of the two mutations found in single heterozygous state in the two YOPD cases is not simple. The Thr12Met and Gly533Arg mutations are both non-conservative amino acid substitutions, targeting highly conserved residues (figure 1B) and as such, have potential pathogenic relevance. The replacement of threonine12 with methionine might also introduce a novel translation initiation codon, leading to the skipping of the first 11 residues in the ATP13A2 protein. Furthermore, these mutations were not identified in control chromosomes, indicating that they are not common polymorphisms. Interestingly, despite the large size of the ATP13A2 protein, we observed not a single frequent missense polymorphism, while all of the frequent exonic SNPs detected were silent variants. This suggests that the ATP13A2 protein has low polymorphism content, 1560 Neurology 68 May 8, 2007
5 at least in the studied populations, adding further relevance to the missense mutations we identified. One possibility is that these mutations are disease-causing in trans with a second mutation, which has escaped detection by the methods used in this study. We did not perform cdna or gene dosage analysis and therefore we could have missed large genomic rearrangements, or mutations in promoter or other regulatory regions. As another possibility, these mutations might act as risk factor for development of YOPD, in combination with mutations in other genes. The screening of the parkin, PINK1, and DJ-1 gene was negative in our three cases with ATP13A2 mutations. Finally, the ATP13A2 mutations might be unrelated to the disease in these two patients, as heterozygous carriers of recessive mutations exist in the population, and are expected to be detected if a sufficient number of individuals is tested. However, this last possibility is unlikely on the basis of the low frequency of juvenile parkinsonism and the even lower frequency of cases attributable to homozygous mutations in this gene. The same debate about the role of single heterozygous mutations applies to the other genes causing recessive forms of YOPD (parkin, PINK1, DJ-1). 9,12-14 Taken as a whole, our data suggest therefore that mutations in the ATP13A2 gene might be relevant for YOPD. Whether mutations or polymorphisms in the ATP13A2 gene are associated with later-onset PD remains unknown and this also deserves further study. ATP13A2 encodes a large, 1,180 amino acids transmembrane protein belonging to the Group 5 P-type ATPase class and displaying lysosomal localization in overexpression studies. 7 The function and substrate specificity of this protein remain unknown, but, intriguingly, the ATP13A2 mrna is highly expressed in the brain, particularly in substantia nigra, and it seems upregulated in the brain of patients with the common late-onset idiopathic PD. 7 Other research lines point to an important role for lysosomes in the pathogenesis of common, lateonset PD. The lysosomes are important for the degradation of the alpha-synuclein protein, 15,16 and heterozygous mutations in the GBA gene, encoding the lysosomal enzyme glucocerebrosidase, are emerging as an important risk factor for Lewy body disorders (PD and Lewy body dementia). 17,18 The clinical phenotype in the original families with homozygous ATP13A2 mutations (KRD) was characterized by additional multisystemic features, such as pyramidal tract signs, supranuclear gaze palsy, and severe cognitive decline. 3,5 On the contrary, in our homozygous case the atypical features were limited to an impaired upward gaze and to moderate brain atrophy. The early motor and psychiatric complications induced by levodopa narrow the therapeutic window, and brisk tendon reflexes are present in this patient; however, these are all common features in juvenile parkinsonism and YOPD, including those caused by parkin mutation. 19 The subacute onset of symptoms described in the original Jordan KRD family was not reported in our case or in the Chilean KRD family. Our case illustrates therefore that homozygous ATP13A2 gene mutations are not invariably associated with the full-blown KRD, but might be found in patients with a milder clinical presentation. One of the patients of the Chilean family described in the original cloning report (Case II-9) also displayed incomplete clinical presentation, with lack of Babinski sign and supranuclear gaze palsy, though severe cognitive deterioration was present in addition to parkinsonism. 7 A milder phenotype could correlate with presence of missense mutations and residual protein function, while the full-blown KRD could be more frequent in those carrying truncating mutations. However, a larger number of cases and mutations are needed to test this hypothesis. The identification of the missense mutation described in this study and of other patients with mutations in this gene might foster the understanding of the function of the ATP13A2 protein, and of the mechanisms of disease caused by its dysfunction. Screening of the ATP13A2 gene should be included in the diagnostic workup of juvenile parkinsonism, especially in, but not limited to, the cases with additional clinical features, such as pyramidal signs, cognitive deterioration, or supranuclear gaze paresis. ACKNOWLEDGMENT The authors thank all patients and relatives for their contributions, and Tom de Vries-Lentsch, Erasmus MC, Rotterdam, for artwork. APPENDIX Members of the Italian Parkinson Genetics Network are as follows: V. Bonifati, Erasmus MC, Rotterdam, The Netherlands; N. Vanacore, National Centre of Epidemiology, Rome; G. Meco, G. Fabbrini, E. Fabrizio, N. Locuratolo, C. Scoppetta, M. Manfredi, A. Berardelli, University La Sapienza, Rome; L. Lopiano, S. Giraudo, B. Bergamasco, University of Torino; C. Tassorelli, C. Pacchetti, G. Nappi, IRCCS Mondino, Pavia; S. Goldwurm, A. Antonini, G. Pezzoli, Parkinson Institute, Istituti Clinici di Perfezionamento, Milan; G. Riboldazzi, G. Bono, Insubria University, Varese; F. Raudino, Hospital Valduce, Como; Mi. Manfredi, Poliambulanza Hospital, Brescia; E. Fincati, University of Verona; M. Tinazzi, A. Bonizzato, Hospital Borgo Trento, Verona; C. Ferracci, Hospital of Belluno; A. Dalla Libera, Boldrini Hospital, Thiene; G. Abbruzzese, R. Marchese, University of Genova; P. Montagna, University of Bologna; P. Marini, F. Massaro, University of Firenze; R. Marconi, Misericordia Hospital, Grosseto; M. Guidi, INRCA Institute, Ancona; C. Minardi, F. Rasi, Bufalini Hospital, Cesena; M. Onofrj, A. Thomas, University of Chieti; F. Stocchi, L. Vacca, IRCCS San Raffaele Pisana, Rome; F. De Pandis, Villa Margherita Hospital, Benevento; M. De Mari, C. Diroma, G. Iliceto, P. Lamberti, University of Bari; V. Toni, G. Trianni, Hospital of Casarano; A. Mauro, Hospital of Salerno; A. De Gaetano, Hos- Neurology 68 May 8,
6 pital of Castrovillari; M. Rizzo, Hospital of Palermo; G. Cossu, Hospital S. Michele AOB G. Brotzu, Cagliari. Additional co-authors are Carlos R.M. Rieder and Maria Luiza Saraiva-Pereira, Hospital de Clínicas de Porto Alegre, Brazil. Received November 15, Accepted in final form February 2, REFERENCES 1. Quinn N, Critchley P, Marsden CD. Young onset Parkinson s disease. Mov Disord 1987;2: Paviour DC, Surtees RA, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord 2004;19: Najim al-din AS, Wriekat A, Mubaidin A, et al. Pallidopyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;89: Davison C. Pallido-pyramidal disease. J Neuropathol Exp Neurol 1954;13: Williams DR, Hadeed A, al-din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005;20: Hampshire DJ, Roberts E, Crow Y, et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J Med Genet 2001;38: Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38: Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, et al. Novel parkin mutations detected in patients with earlyonset Parkinson s disease. Mov Disord 2005;20: Bonifati V, Rohe CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005;65: Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299: Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson s Disease Rating Scale: Recent developments in Parkinson s disease. New York: Macmillan, 1987: Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson s disease. Ann Neurol 2003;53: Hedrich K, Hagenah J, Djarmati A, et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;63: Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson s disease? Ann Neurol 2006;60: Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004;24: Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004;305: Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson s disease in Ashkenazi Jews. N Engl J Med 2004;351: Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67: Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003;54: Disagree? Agree? Have a Question? Have an Answer? Respond to an article in Neurology through our online Correspondence system: Visit Access specific article on which you would like to comment Click on Correspondence: Submit a response in the content box Enter contact information Upload your Correspondence Press Send Response Correspondence will then be transmitted to the Neurology Editorial Office for review. Correspondence must be received within six weeks of the publication date of the article. Selected correspondence will subsequently appear in the print Journal. See our Information for Authors at for format requirements Neurology 68 May 8, 2007
PINK1 Mutations Are Associated with Sporadic Early-Onset Parkinsonism
PINK1 Mutations Are Associated with Sporadic Early-Onset Parkinsonism Enza Maria Valente, MD, PhD, 1 Sergio Salvi, BSc, 1 Tamara Ialongo, MD, 2 Roberta Marongiu, BSc, 1 Antonio Emanuele Elia, MD, 2 Viviana
More informationNovel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
Neurogenetics (2011) 12:33 39 DOI 10.1007/s10048-010-0259-0 ORIGINAL ARTICLE Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability Lucio Santoro & Guido J. Breedveld &
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More informationNIH Public Access Author Manuscript Neurology. Author manuscript; available in PMC 2013 April 12.
NIH Public Access Author Manuscript Published in final edited form as: Neurology. 2007 September 18; 69(12): 1270 1277. doi:10.1212/01.wnl.0000276989.17578.02. Mutations in the glucocerebrosidase gene
More informationGenotypic and phenotypic overlaps in Parkinson s disease and parkinsonisms
Genotypic and phenotypic overlaps in Parkinson s disease and parkinsonisms Enza Maria Valente CSS-Mendel Institute, Rome University of Salerno The «shaking palsy»: clinica features Involuntary tremulous
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationGenetic Parkinson s studying the few to treat the many
Edinburgh Talk 01.12.12 Genetic Parkinson s studying the few to treat the many Miratul Muqit, Wellcome Trust Intermediate Fellow, Honorary Consultant Neurologist, MRC Protein Phosphorylation Unit, University
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease
More informationSupplementary data Multiple hit hypotheses for dopamine neuron loss in Parkinson s disease
Supplementary data Multiple hit hypotheses for dopamine neuron loss in Parkinson s disease David Sulzer Departments of Neurology, Psychiatry and Pharmacology, Black 309, 650 West, 168th Street, Columbia
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationPhenotypic Characteristics of Zambian patients with Parkinson's Disease
ORIGINAL PAPER Medical Journal of Zambia, Vol. 37, No. 3 (2010) Phenotypic Characteristics of Zambian patients with Parkinson's Disease M. Atadzhanov Department of Internal Medicine, School of Medicine,
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationClinical Spectrum of Kufor-Rakeb Syndrome in the Chilean Kindred with ATP13A2 Mutations
Movement Disorders Vol. 25, No. 12, 2010, pp. 1929 1937 Ó 2010 Movement Disorder Society Clinical Spectrum of Kufor-Rakeb Syndrome in the Chilean Kindred with ATP13A2 Mutations Maria I. Behrens, MD, PhD,
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationParkinson disease is one of the most common neurodegenerative diseases associated with
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD F-Box Only Protein 7 Gene in Parkinsonian-Pyramidal Disease Hao Deng, MD, PhD; Hui Liang, MD; Joseph Jankovic, MD Parkinson disease is one of the
More informationDifferential Diagnosis of Hypokinetic Movement Disorders
Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease
More informationvariant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still
157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationObjectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit
Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationAdvances in genetic diagnosis of neurological disorders
Acta Neurol Scand 2014: 129 (Suppl. 198): 20 25 DOI: 10.1111/ane.12232 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Review Article Advances in genetic diagnosis
More informationClinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.
UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationPsych 3102 Lecture 3. Mendelian Genetics
Psych 3102 Lecture 3 Mendelian Genetics Gregor Mendel 1822 1884, paper read 1865-66 Augustinian monk genotype alleles present at a locus can we identify this? phenotype expressed trait/characteristic can
More informationPOTENTIAL LINK BETWEEN GAUCHER DISEASE PATHWAYS
POTENTIAL LINK BETWEEN GAUCHER DISEASE PATHWAYS AND THOSE OF PARKINSON DISEASE Hanna Rosenbaum, MD Hematology and Bone Marrow Transplantation Rambam Medical Center and Bruce Rappaport Faculty of Medicine
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationPoint Mutations at -Synuclein Gene are not Found in Korean Familial Parkinson s Disease
Point Mutations at -Synuclein Gene are not Found in Korean Familial Parkinson s Disease Chul Hyoung Lyoo, M.D., Hyun Sook Kim, M.D., Yong Duk Kim, M.D., Jin Ho Kim, M.D.*, Myung Sik Lee, M.D. Department
More informationFOUNDATION OF UNDERSTANDING PARKINSON S DISEASE
FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationAn approach to movement disorders. Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London
An approach to movement disorders Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London Neurology Diagnosis Two main questions: What parts of the nervous
More informationParkinson s disease: A genetic perspective
MINIREVIEW Parkinson s disease: A genetic perspective Andrea C. Belin and Marie Westerlund Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden Keywords dopamine; Lewy body; linkage; mitochondria;
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationHeterozygous parkin Point Mutations Are as Common in Control Subjects as in Parkinson s Patients
Heterozygous parkin Point Mutations Are as Common in as in Parkinson s Patients Denise M. Kay, PhD, 1 Dawn Moran, BS, 2,3 Lina Moses, BS, 1 Parvoneh Poorkaj, PhD, 2 4 Cyrus P. Zabetian, MD, MS, 2,5 John
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationMendelian forms of Parkinson s disease
Mendelian forms of Parkinson s disease Thomas Gasser To cite this version: Thomas Gasser. Mendelian forms of Parkinson s disease. BBA - Molecular Basis of Disease, Elsevier, 2009, 1792 (7), pp.587. .
More informationEpidemiology and etiology of Parkinson s disease: a review of the evidence
Epidemiology and etiology of Parkinson s disease: a review of the evidence Karin Wirdefeldt, Hans-Olov Adami, Philip Cole, Dimitrios Trichopoulos, Jack Mandel To cite this version: Karin Wirdefeldt, Hans-Olov
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationFreezing of gait in patients with advanced Parkinson s disease
J Neural Transm (2001) 108: 53 61 Freezing of gait in patients with advanced Parkinson s disease N. Giladi, T. A. Treves, E. S. Simon, H. Shabtai, Y. Orlov, B. Kandinov, D. Paleacu, and A. D. Korczyn Movement
More informationExploding Genetic Knowledge in Developmental Disabilities. Disclosures. The Genetic Principle
Exploding Genetic Knowledge in Developmental Disabilities How to acquire the data and how to make use of it Elliott H. Sherr MD PhD Professor of Neurology & Pediatrics UCSF Disclosures InVitae: clinical
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More informationCHAPTER IV RESULTS Microcephaly General description
47 CHAPTER IV RESULTS 4.1. Microcephaly 4.1.1. General description This study found that from a previous study of 527 individuals with MR, 48 (23 female and 25 male) unrelated individuals were identified
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationDisorders of Movement M A R T I N H A R L E Y N E U R O L O G Y
Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Educational Objectives Improved history taking in patients with movement disorders. Develop a systematic approach to observing and describing
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationRe-emergent tremor in Parkinson s disease: the effect of dopaminergic treatment
ORIGINAL ARTICLE Re-emergent tremor in Parkinson s disease: the effect of dopaminergic treatment D. Belvisi a, A. Conte a,b, C. Cutrona b, M. Costanzo b, G. Ferrazzano a, G. Fabbrini a,b and A. Berardelli
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationORIGINAL CONTRIBUTION. Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism
ORIGINAL CONTRIBUTION Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism Jeremy Kraff, MD; Hiu-Tung Tang, BA; Roberto Cilia, MD; Margherita Canesi, MD; Gianni Pezzoli, MD; Stefano
More informationPPMI Genetics Cohorts
PPMI Genetics Cohorts Ken Marek PPMI Genetics Kickoff Sept 16, 2013 New York, NY PPMI Genetic Cohort/Registry Symptomatic Neuron Function Prodromal P-PPMI Gen P-PPMI PPMI Diagnosis PPMI- Gen 2 PPMI-Genetics
More informationHuman Genetic Diseases (non mutation)
mutation) Pedigrees mutation) 1. Autosomal recessive inheritance: this is the inheritance of a disease through a recessive allele. In order for the person to have the condition they would have to be homozygous
More informationMRC-Holland MLPA. Description version 19;
SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL
More informationWHAT GENETICS TELLS US ABOUT THE CAUSES AND MECHANISMS OF PARKINSON S DISEASE
WHAT GENETICS TELLS US ABOUT THE CAUSES AND MECHANISMS OF PARKINSON S DISEASE Olga Corti, Suzanne Lesage, and Alexis Brice Physiol Rev 91: 1161 1218, 2011 doi:10.1152/physrev.00022.2010 Université Pierre
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationlega italiana per la lotta contro la malattia di parkinson le sindromi extrapiramidali e le demenze
LIMPE lega italiana per la lotta contro la malattia di parkinson le sindromi extrapiramidali e le demenze Web site: http://www.parkinson-limpe.it/ XXVIII National Congress Alba (Cuneo) 7 9 November 2001
More informationPedigree Construction Notes
Name Date Pedigree Construction Notes GO TO à Mendelian Inheritance (http://www.uic.edu/classes/bms/bms655/lesson3.html) When human geneticists first began to publish family studies, they used a variety
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationSingle Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions
Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationChapter 18 Genetics of Behavior. Chapter 18 Human Heredity by Michael Cummings 2006 Brooks/Cole-Thomson Learning
Chapter 18 Genetics of Behavior Behavior Most human behaviors are polygenic and have significant environmental influences Methods used to study inheritance include Classical methods of linkage and pedigree
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationMAXIMIZING FUNCTION IN PARKINSON S DISEASE
1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):
More informationID # COMPLETED: YES.. 1 DATE NO... 5 NEUROLOGICAL EXAM
ID # COMPLETED: YES.. 1 DATE NO... 5 NEUROLOGICAL EXAM VIDEOTAPED: YES.. 1 NO... 5 COMMENT: NEUROLOGICAL EXAM "Normal, Abnormal, Other, Can't execute or Missing for each question. Always complete specify
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationRare genetic mutations shed light on the pathogenesis of Parkinson disease
PERSPECTIVE Neurodegeneration Serge Przedborski, Series Editor Rare genetic mutations shed light on the pathogenesis of Parkinson disease Ted M. Dawson 1,2,3 and Valina L. Dawson 1,2,3,4 1 Institute for
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationValidation of the Italian version of the Movement Disorder Society Unified Parkinson s Disease Rating Scale
DOI 10.1007/s10072-012-1112-z ORIGINAL ARTICLE Validation of the version of the Movement Disorder Society Unified Parkinson s Disease Rating Scale Angelo Antonini Giovanni Abbruzzese Luigi Ferini-Strambi
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationAbstract. Introduction
Brazilian Journal of Medical and Biological Research (2003) 36: 1403-1407 Thr(118)Met in Charcot-Marie-Tooth disease ISSN 0100-879X 1403 Thr(118)Met amino acid substitution in the peripheral myelin protein
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More informationDate of Referral: Enhanced Primary Care Pathway: Parkinson s Disease
Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationClinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan)
Clinical Spectrum and Genetic Mechanism of GLUT1-DS Yasushi ITO (Tokyo Women s Medical University, Japan) Glucose transporter type 1 (GLUT1) deficiency syndrome Mutation in the SLC2A1 / GLUT1 gene Deficiency
More information10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.
Deep Brain Stimulation in the Treatment of Movement Disorders Disclosures None Eleanor K Orehek, M.D. Movement Disorders Specialist Noran Neurological Clinic 1 2 Objectives To provide an overview of deep
More informationIdentification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome
Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome L.H. Cao 1, B.H. Kuang 2, C. Chen 1, C. Hu 2, Z. Sun 1, H. Chen 2, S.S. Wang
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationEffects of genetic rare variants. on Parkinson s disease in the Korean population
Effects of genetic rare variants on Parkinson s disease in the Korean population Won Chan Kim Department of Medicine The Graduate School, Yonsei University Effects of genetic rare variants on Parkinson
More informationOriginal Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III
2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:
More informationNIH Public Access Author Manuscript Mov Disord. Author manuscript; available in PMC 2009 May 18.
NIH Public Access Author Manuscript Published in final edited form as: Mov Disord. 2008 August 15; 23(11): 1602 1605. doi:10.1002/mds.22161. Emergence of Parkinsons Disease in Essential Tremor: A Study
More informationLRRK2 G2019S mutation and Parkinson s disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample
Parkinsonism and Related Disorders 12 (2006) 410 419 www.elsevier.com/locate/parkreldis LRRK2 G2019S mutation and Parkinson s disease: A clinical, neuropsychological and neuropsychiatric study in a large
More informationIVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois
FERTILITY AND STERILITY VOL. 80, NO. 4, OCTOBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. CASE REPORTS Preimplantation
More information